四环医药(00460.HK):轩竹生物(02575.HK)的安奈拉唑钠治疗反流性食管炎III期临床研究数据于UEG Week 2026展示

智通财经
Oct 21
【四环医药(00460.HK):轩竹生物(02575.HK)的安奈拉唑钠治疗反流性食管炎III期临床研究数据于UEG Week 2026展示】智通财经APP讯,四环医药(00460.HK)公布,该集团旗下非全资附属公司轩竹生物科技股份有限公司(轩竹生物,股份代号:02575.HK)自主研发的国家1类创新药安奈拉唑钠肠溶片治疗反流性食管炎的III期注册临床研究结果,于近日在西班牙巴塞罗那举行的第34届欧洲消化疾病周(UEG Week 2026)大会上,以Late Breaking Abstract(LB25)口头报告形式进行展示。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10